Alimera nabs US commercial rights for Yutiq
May 18th 2023Today, Alimera Sciences announced that they have acquired the US commercial rights of Yutiq (fluocinolone acetonide intravitreal insert) 0.18mg for the treatment of chronic non-infectious uveitis. Yutiq now joins Iluvien (fluocinolone acetonide intravitreal insert) 0.19 mg for DME in Alimera’s retina portfolio.
DR:EAM study: Exploring eye drops for diabetic retinopathy
The DR:EAM study in investigating novel eye drop OTT-166 for the treatment of diabetic retinopathy in hopes of reducing treatment burden for patients.
IKA Keratoconus Symposium 2023: New data presented for epi-on cross-linking
John D. Gelles, OD, and Steven A. Greenstein, MD, share some insights into the new data on corneal cross-linking presented at IKA Keratoconus Symposium.
IKA Keratoconus Symposium 2023: In-person white paper development, live patient Q&A
April 22nd 2023President and CEO of the International Keratoconus Academy Andrew Morgenstern, OD, FAAO, FNAP, shares some snippets about the live white paper development session and the patient Q&A happening at the inaugural IKA Keratoconus Symposium.
SECO 2023: Sleep disorders impact eye disease
Paul Chous, MA, OD, FAAO, shares key highlights from his 2023 SECO presentation looking at sleep disorders and how they play a role in eye disease.